Entero Therapeutics, Inc. – NASDAQ:ENTO
Entero Therapeutics stock price today
Entero Therapeutics stock price monthly change
Entero Therapeutics stock price quarterly change
Entero Therapeutics key metrics
Market Cap | 3.06M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEntero Therapeutics stock price history
Entero Therapeutics stock forecast
Entero Therapeutics financial statements
| 2015 | 0 | -5.93M | |
|---|---|---|---|
| 2017 | 0 | -11.09M | |
| 2020 | 0 | -32.67M | |
| 2023 | 0 | -15.79M |
| 2014 | 6575 | 2.43K | 36.96% |
|---|---|---|---|
| 2015 | 6685 | 8.81K | 131.86% |
| 2017 | 6550738 | 3.81M | 58.3% |
| 2023 | 6883195 | 3.28M | 47.66% |
| Mar 2017 | -1.16K | 0 | -77 |
|---|---|---|---|
| Jun 2017 | -2.25K | -20 | 5.59K |
| Sep 2017 | -1.29K | -10 | 337 |
| Dec 2017 | -2.46K | 0 | 159 |
Entero Therapeutics alternative data
| Jun 2024 | 9 |
|---|---|
| Jul 2024 | 9 |
| Dec 2024 | 9 |
Entero Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2024 | 0 | 1910 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ROMANO SARAH officer: Chief Fi.. | Common Stock | 621 | $1.07 | $664 | ||
Sale | SAPIRSTEIN JAMES director, officer: Chairman and.. | Common Stock | 1,289 | $1.07 | $1,379 |
-
What's the price of Entero Therapeutics stock today?
One share of Entero Therapeutics stock can currently be purchased for approximately $1.89.
-
When is Entero Therapeutics's next earnings date?
Unfortunately, Entero Therapeutics's (ENTO) next earnings date is currently unknown.
-
Does Entero Therapeutics pay dividends?
No, Entero Therapeutics does not pay dividends.
-
How much money does Entero Therapeutics make?
Entero Therapeutics has a market capitalization of 3.06M.
-
What is Entero Therapeutics's stock symbol?
Entero Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ENTO".
-
What is Entero Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Entero Therapeutics?
Shares of Entero Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Entero Therapeutics have?
As Dec 2024, Entero Therapeutics employs 9 workers.
-
When Entero Therapeutics went public?
Entero Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 11 Oct 2016.
-
What is Entero Therapeutics's official website?
The official website for Entero Therapeutics is firstwavebio.com.
-
Where are Entero Therapeutics's headquarters?
Entero Therapeutics is headquartered at 777 Yamato Road, Boca Raton, FL.
-
How can i contact Entero Therapeutics?
Entero Therapeutics's mailing address is 777 Yamato Road, Boca Raton, FL and company can be reached via phone at +56 15897020.
Entero Therapeutics company profile:
Entero Therapeutics, Inc.
firstwavebio.comNASDAQ
9
Biotechnology
Healthcare
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Boca Raton, FL 33431
:
ISIN: US33749P4081
:
